Role of RANK ligand in mediating increased bone resorption in early postmenopausal women.

By G. Eghbali-Fatourechi, S. Khosla, A. Sanyal, W. J. Boyle, D. Lacey, B. Riggs. Journal of Clinical Investigation, 2003

804 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Effects of obesity on bone metabolism (2011, neutral): “RANKL [39,43,44].”
Estrogen and the Skeleton (2012, positive): “Combined in vitro and in vivo studies have demonstrated that estrogen suppresses RANKL production by osteoblastic, T- and B-cells (34) and also increases production of the decoy receptor for RANKL, osteoprotegerin (OPG) (35, 36).”
Denosumab and bisphosphonates: different mechanisms of action and effects. (2011, background): “Increased expression and production of RANK ligand (RANKL), as seen with estrogen deprivation, is a central mechanism of osteoclast activation and increased bone resorption [8,9].”
Genetic regulation of osteoclast development and function (2003, background): “A recent seminal report shows that women who lack oestrogen have higher expression of the important osteoclastogenic molecule RANKL on both osteoblasts and lymphocyte”
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. (2008, neutral): “and inversely with serum estradiol levels (76).”